T1	Participants 73 118	childhood-onset obsessive-compulsive disorder
T2	Participants 126 191	children with childhood-onset obsessive-compulsive disorder (OCD)
T3	Participants 392 526	study examined the efficacy of riluzole, a glutamatergic modulator, as an adjunctive therapy for children with treatment-resistant OCD
T4	Participants 582 821	60 treatment-resistant children and adolescents (mean age=14.5 ± 2.4 years), with moderate to severe OCD (mean Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)=28.2 ± 3.7), 17 of whom also had concomitant autism spectrum disorder
T5	Participants 944 973	Fifty-nine subjects completed
